Azelaic acid works.
Here is what the science shows.

Azelaic acid is a naturally occurring dicarboxylic acid found in grains such as wheat, rye, and barley. When applied topically, it acts on acne through four distinct pathways, each targeting a different step in the acne formation cascade.

The first mechanism is antibacterial activity. Azelaic acid inhibits the synthesis of proteins in Cutibacterium acnes (formerly Propionibacterium acnes), the anaerobic bacteria that colonizes sebaceous follicles and drives the inflammatory response behind papules and pustules. Importantly, azelaic acid is bacteriostatic rather than bactericidal at standard concentrations — it stops bacterial growth rather than killing cells outright. This distinction matters clinically: bacteria are less likely to develop resistance to bacteriostatic agents, and unlike benzoyl peroxide, no significant resistance to azelaic acid has been reported in the literature after decades of use.

The second mechanism is anti-keratinization. Azelaic acid normalizes the abnormal thickening of the skin cells lining the follicular canal — a process called follicular hyperkeratinization — which is the earliest step in comedone formation. By reducing this thickening, azelaic acid addresses the root of blackheads and whiteheads rather than only the inflammatory lesions that develop from them. This is the mechanism that makes it effective for comedonal as well as inflammatory acne.

The third mechanism is anti-inflammatory. Azelaic acid scavenges reactive oxygen species (free radicals) generated by neutrophils during the skin's inflammatory response. It also reduces levels of pro-inflammatory cytokines at the site of application. This means it can reduce the redness, swelling, and tenderness of active inflammatory lesions — not just prevent new ones from forming. The fourth mechanism, anti-tyrosinase activity, governs its effect on pigmentation and is discussed in detail in the section on hyperpigmentation below.

Azelaic acid has been tested against the two most commonly prescribed topical acne treatments — benzoyl peroxide and tretinoin — in multiple randomized controlled trials, and the results reveal a nuanced picture of where it excels and where trade-offs exist.

Against benzoyl peroxide, a pivotal 20% azelaic acid cream was compared to 5% benzoyl peroxide in a large multicenter trial published in the British Journal of Dermatology. Both treatments produced significant reductions in inflammatory and non-inflammatory lesion counts over 12 weeks, with statistically equivalent efficacy. The critical difference was tolerability: patients in the azelaic acid group experienced significantly fewer adverse events — less dryness, scaling, and erythema — than those using benzoyl peroxide. The researchers concluded that azelaic acid represents a comparable therapeutic option with a superior tolerability profile.

When compared to tretinoin, a 1992 study in the Journal of the American Academy of Dermatology found that 20% azelaic acid cream produced equivalent reductions in comedonal and inflammatory lesion counts to 0.05% tretinoin over 24 weeks. Tretinoin produced more rapid improvement in the first 8 weeks, but azelaic acid caught up by week 12 and showed better tolerability throughout — specifically less initial retinoid dermatitis, the purging period of redness and peeling that causes many patients to abandon tretinoin before it works.

A 2020 network meta-analysis published in the Journal of the American Academy of Dermatology analyzed 221 randomized trials covering 18 treatment categories and found that 15-20% azelaic acid achieved clinically meaningful reductions in both inflammatory and non-inflammatory lesions across study populations. While combination approaches (such as tretinoin plus a topical antibiotic) showed higher peak efficacy, azelaic acid's single-agent performance was particularly strong for patients who could not tolerate first-line therapies or who needed a pregnancy-safe option.

Azelaic acid is available at two distinct concentration tiers, each with different evidence bases, regulatory classifications, and practical implications for patients.

Prescription formulations come in 15% and 20% concentrations, available as gels, foams, and creams. The 20% cream (Azelex) and 15% gel (Finacea) have FDA-approved indications for acne and rosacea, respectively, backed by the pivotal clinical trials described above. These concentrations deliver the antibacterial and anti-keratinization effects that the research most directly supports. The 15% gel formulation tends to absorb faster and is often preferred for oily or combination skin, while the 20% cream may be more appropriate for drier skin types.

Over-the-counter formulations typically range from 7% to 10%, with 10% being the most common concentration in branded skincare products. While 10% azelaic acid has not been the subject of the same volume of head-to-head acne trials as prescription concentrations, a 2022 systematic review in Dermatologic Therapy analyzed available studies and found that 10% formulations produced clinically significant reductions in mild-to-moderate acne, though the magnitude of effect was generally lower than that seen with 15–20% prescription concentrations. For mild comedonal or early inflammatory acne, a 10% OTC formulation is a reasonable starting point; for moderate inflammatory acne, prescription-strength formulations are more likely to achieve adequate results.

A practical consideration often overlooked in product discussions is the vehicle — the base formula carrying the active ingredient. Azelaic acid is pH-sensitive: it requires an acidic vehicle (pH approximately 3.5–4.5) to maintain stability and effective skin penetration. Budget formulations that compromise on vehicle quality may deliver less active ingredient to the skin despite listing the same percentage on the label. When evaluating OTC options, look for brands that provide full formulation information and avoid those that combine azelaic acid with alkaline ingredients that may neutralize it.

One of azelaic acid's most clinically significant properties is its ability to reduce post-inflammatory hyperpigmentation (PIH) — the flat, darkened patches that remain after an acne lesion resolves. PIH is driven by the overproduction of melanin in response to inflammation: as the immune system attacks acne bacteria, the inflammatory cascade signals melanocytes (pigment-producing cells) to overproduce melanin, which accumulates in the epidermis and sometimes the dermis as a dark discoloration.

Azelaic acid addresses PIH through inhibition of tyrosinase, the rate-limiting enzyme in melanin synthesis. By reducing tyrosinase activity, it slows melanin overproduction at the site of inflammation — and it does so selectively, meaning it does not affect normal melanocytes that are not already hyperactivated. This selectivity is the critical advantage over older brightening agents like hydroquinone, which inhibit tyrosinase non-selectively and can paradoxically cause rebound hyperpigmentation or ochronosis (permanent bluish-black discoloration) with long-term use.

For people with Fitzpatrick skin types IV through VI — skin tones that range from olive to dark brown to very dark brown — this distinction is not merely academic. These skin types have more reactive melanocytes and are significantly more prone to PIH after acne. They are also more vulnerable to post-inflammatory hypopigmentation (loss of pigment) from strong topical treatments. Benzoyl peroxide can cause bleaching at application sites; hydroquinone carries a risk of irreversible depigmentation with misuse; tretinoin can cause erythema and irritation-driven PIH during the adaptation phase. Azelaic acid does not cause hypopigmentation at therapeutic doses and does not bleach fabrics, making it one of the safest PIH-targeting options for darker skin tones.

A 1996 double-blind trial published in the International Journal of Dermatology compared 20% azelaic acid cream to 4% hydroquinone cream in patients with facial hyperpigmentation, finding equivalent efficacy on PIH reduction over six months, with a significantly better safety profile for azelaic acid. For patients dealing with both active acne and its discoloring aftermath, azelaic acid is the rare agent that addresses both simultaneously.

One of the most practically important aspects of azelaic acid's clinical profile is its classification as Pregnancy Category B by the FDA — meaning animal reproduction studies have not demonstrated fetal risk and no adequate controlled studies exist in pregnant women, but the available evidence does not indicate a risk of fetal harm. This designation places azelaic acid in the same safety tier as erythromycin and clindamycin gel for topical acne treatment during pregnancy, and it is specifically recommended by the American College of Obstetricians and Gynecologists as an acceptable topical acne treatment option.

Pregnancy acne is common and often severe due to the hormonal surges of the first and second trimesters. Many first-line acne treatments are contraindicated in pregnancy: isotretinoin (Accutane) is absolutely contraindicated due to teratogenicity; topical retinoids carry a Category C designation with theoretical risk; doxycycline is contraindicated after 15 weeks of gestation. The pregnant patient with moderate inflammatory acne has a narrow field of safe, effective options, and azelaic acid occupies valuable ground within it.

Beyond pregnancy, azelaic acid's tolerability profile makes it useful for populations that struggle with first-line treatments. Patients with sensitive skin or rosacea-prone skin who cannot tolerate the initial irritation of retinoids often find azelaic acid both effective and well-tolerated. Its anti-inflammatory mechanism directly addresses the erythema component of rosacea, which is why it has FDA approval for that indication at 15%. Patients who have been on extended courses of topical antibiotics and are concerned about resistance will find in azelaic acid an antibacterial agent with no documented resistance development. And patients who have tried benzoyl peroxide and found it incompatible with their lifestyle — because of bleaching, excessive dryness, or sensitivity — have a well-evidenced alternative.

It is worth noting that azelaic acid is not a rescue treatment for severe inflammatory acne or nodulocystic disease. For moderate-to-severe presentations, it is most appropriately used as part of a combination regimen or as a maintenance therapy after systemic treatment has brought acne under initial control. For mild-to-moderate acne, particularly when PIH is a concern, it stands solidly as a first-line monotherapy option.

Azelaic acid has one important clinical reality that catches many users off guard: it is slow. Most people do not see meaningful improvement until four to eight weeks of consistent twice-daily use, and full benefit — particularly the reduction of post-inflammatory hyperpigmentation — may not be apparent until twelve to sixteen weeks. This timeline is clinically well-established but not well-communicated, which is why azelaic acid has a high abandonment rate among impatient users who stop at three or four weeks, just before results begin to emerge.

Systematic tracking transforms this problem. By recording your skin condition daily — noting inflammatory lesion count, redness, and PIH extent — you create a baseline that makes incremental improvement visible. Improvement in acne is rarely a dramatic before/after; it is a gradual trend in which average lesion counts slowly decline and flares become less severe. Without a daily record, these improvements are easy to miss and easy to discount. With a timestamped log, you can look back at six weeks of data and see objectively whether your skin is trending in the right direction, even if today's face looks similar to last week's.

Tracking also helps distinguish what azelaic acid is doing versus what your other variables are doing. If you introduce azelaic acid during a period of significant dietary or lifestyle change, your skin will certainly change — but you will not know what drove it. By tracking potential trigger variables alongside your treatment, you can hold confounders constant in your analysis. If your sleep quality worsened in week six and your skin worsened too, that context prevents you from falsely attributing the worsening to azelaic acid.

ClearSkin is built specifically for this kind of longitudinal self-monitoring. Logging takes under a minute per day, and the trend visualization shows you eight-week and twelve-week trajectories rather than just today's snapshot. For a treatment like azelaic acid — where the evidence is strong but the timeline is long — that longitudinal view is the difference between persisting to the point of results and giving up just short of them.